drugset / Trial / NCT00354562

A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer

NCT00354562

Phase 1/2 Terminated 75 enrolled Abbott
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine the efficacy of ABT-751 when administered in combination with standard docetaxel in subjects with advanced or metastatic NSCLC.

Timeline

Start
2007-02
Primary completion
2008-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator ABT-751 Other / unclassified 200 mg
Comparator Docetaxel Small molecule